Insmed Incorporated Share Price Today: Live Updates & Key Insights

Insmed Incorporated share price today is $136.87, up -5.56%. The stock opened at $142.39 against the previous close of $144, with an intraday high of $143.19 and low of $135.82.

Insmed Incorporated Share Price Chart

Insmed Incorporated

us-stock
To Invest in {{usstockname}}
us-stock

Insmed Incorporated Share Price Performance

$136.87 -0.0556(-5.56%) INSM at 23 Mar 2026 01:40 PM Biotechnology
Lowest Today 135.82
Highest Today 143.19
Today’s Open 142.39
Prev. Close 144
52 Week High 212.75
52 Week Low 60.40
Day’s Range: Low 135.82 High 143.19
52-Week Range: Low 60.40 High 212.75
1 day return -
1 Week return -5.95
1 month return -14.47
3 month return -22.64
6 month return -6.18
1 year return +71.43
3 year return +736.92
5 year return +261.99
10 year return -

Insmed Incorporated Institutional Holdings

JPMorgan Chase & Co 21.38

Vanguard Group Inc 9.78

Darwin Global Management, Ltd. 9.49

BlackRock Inc 5.74

JPMorgan Large Cap Growth I 4.93

JPM US Large Cap Growth-MA 4.88

FMR Inc 4.61

T. Rowe Price Associates, Inc. 3.22

Vanguard Total Stock Mkt Idx Inv 3.12

Baker Bros Advisors LP 3.06

Capital Research & Mgmt Co - Division 3 2.39

Artisan Partners Limited Partnership 2.25

RTW INVESTMENTS, LLC 2.25

Invesco QQQ Trust 2.10

D. E. Shaw & Co LP 2.02

Geode Capital Management, LLC 1.99

Orbis Allan Gray Ltd 1.94

State Street Corp 1.85

American Funds Growth Fund of Amer A 1.60

Capital Group Growth Fnd of Amer Comp 1.60

NORGES BANK 1.35

Ameriprise Financial Inc 1.26

Vanguard Small Cap Index 1.12

Vanguard Mid Cap Index Institutional 1.07

Vanguard Institutional Extnd Mkt Idx Tr 1.07

Franklin Resources Inc 0.99

JPMCB Large Cap Growth CF-A 0.97

NWI Management LP 0.95

Amvescap Plc. 0.93

UBS Group AG 0.76

iShares Biotechnology ETF 0.73

JPM US Mid Cap Growth-Composite 0.73

JPMorgan Mid Cap Growth I 0.72

JPMorgan Growth Advantage A 0.71

Vanguard Growth Index Investor 0.68

Vanguard Small Cap Growth Index Inv 0.62

iShares Russell Mid-Cap Growth ETF 0.61

State St Russell Sm/Mid Cp® Indx SL Cl I 0.57

Fidelity Extended Market Index 0.52

Orbis Global Equity Investor 0.50

Insmed Incorporated Market Status

Strong Buy: 14

Buy: 5

Hold: 0

Sell: 0

Strong Sell: 0

Insmed Incorporated Fundamentals

Market Cap 29315.06 M

PB Ratio 42.0034

PE Ratio 0.0

Enterprise Value 30196.10 M

Total Assets 2264.56 M

Volume 4561590

Insmed Incorporated Company Financials

Annual Revenue FY25:606423000 606.4M, FY24:363707000 363.7M, FY23:280815000 280.8M, FY22:245358000 245.4M, FY21:188461000 188.5M

Annual Profit FY25:481548000 481.5M, FY24:277965000 278.0M, FY23:220616000 220.6M, FY22:190232000 190.2M, FY21:144309000 144.3M

Annual Net worth FY25:-1276775000 -1276.8M, FY24:-913772000 -913.8M, FY23:-723629000 -723.6M, FY22:-481534000 -481.5M, FY21:-434654000 -434.7M

Quarterly Revenue Q4/2025:263843000 263.8M, Q3/2025:142342000 142.3M, Q2/2025:107415000 107.4M, Q1/2025:92823000 92.8M, Q4/2024:104442000 104.4M

Quarterly Profit Q4/2025:217686000 217.7M, Q3/2025:112977000 113.0M, Q2/2025:79340000 79.3M, Q1/2025:71545000 71.5M, Q4/2024:78291000 78.3M

Quarterly Net worth Q4/2025:-328485000 -328.5M, Q3/2025:-370021000 -370.0M, Q2/2025:-321686000 -321.7M, Q1/2025:-256583000 -256.6M, Q4/2024:-235548000 -235.5M

About Insmed Incorporated & investment objective

Company Information Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Organisation Biotechnology

Employees 1664

Industry Biotechnology

CEO Mr. William H. Lewis J.D., M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Insmed Incorporated FAQs

What is the share price of Insmed Incorporated today?

The current share price of Insmed Incorporated is $136.87.

Can I buy Insmed Incorporated shares in India?

Yes, Indian investors can buy Insmed Incorporated shares by opening an international trading and demat account with Motilal Oswal.

How to buy Insmed Incorporated shares in India?

You can easily invest in Insmed Incorporated shares from India by:

Can I buy fractional shares of Insmed Incorporated?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Insmed Incorporated?

Insmed Incorporated has a market cap of $29315.06 M.

In which sector does Insmed Incorporated belong?

Insmed Incorporated operates in the Biotechnology sector.

What documents are required to invest in Insmed Incorporated stocks?

To invest, you typically need:

What is the PE and PB ratio of Insmed Incorporated?

The PE ratio of Insmed Incorporated is N/A and the PB ratio is 42.00.